<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(4)</volume><submitter>Hou N</submitter><funding>Westlake Education Foundation</funding><funding>Tencent</funding><pubmed_abstract>The 3C-like protease (3CLpro) of SARS-CoV-2 is an attractive drug target for developing antivirals against SARS-CoV-2. A few small molecule inhibitors of 3CLpro are in clinical trials for COVID-19 treatments, and more inhibitors are under development. One limiting factor for 3CLpro inhibitors development is that the cellular activities of such inhibitors should be evaluated in Biosafety Level 3 (BSL-3) laboratories. Here, we design DNA-coded biosensors that can be used in BSL-2 laboratories to set up cell-based assays for 3CLpro inhibitor discovery. The biosensors were constructed by linking a green fluorescent protein (GFP2) to the N-terminus and a Renilla luciferase (RLuc8) to the C-terminus of SARS-CoV-2 3CLpro, with the linkers derived from the cleavage sequences of 3CLpro. After overe</pubmed_abstract><journal>Microbiology spectrum</journal><pagination>e0255921</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9430692</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>BRET-Based Self-Cleaving Biosensors for SARS-CoV-2 3CLpro Inhibitor Discovery.</pubmed_title><pmcid>PMC9430692</pmcid><pubmed_authors>Zhu Y</pubmed_authors><pubmed_authors>Hou N</pubmed_authors><pubmed_authors>Peng C</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Hu Q</pubmed_authors></additional><is_claimable>false</is_claimable><name>BRET-Based Self-Cleaving Biosensors for SARS-CoV-2 3CLpro Inhibitor Discovery.</name><description>The 3C-like protease (3CLpro) of SARS-CoV-2 is an attractive drug target for developing antivirals against SARS-CoV-2. A few small molecule inhibitors of 3CLpro are in clinical trials for COVID-19 treatments, and more inhibitors are under development. One limiting factor for 3CLpro inhibitors development is that the cellular activities of such inhibitors should be evaluated in Biosafety Level 3 (BSL-3) laboratories. Here, we design DNA-coded biosensors that can be used in BSL-2 laboratories to set up cell-based assays for 3CLpro inhibitor discovery. The biosensors were constructed by linking a green fluorescent protein (GFP2) to the N-terminus and a Renilla luciferase (RLuc8) to the C-terminus of SARS-CoV-2 3CLpro, with the linkers derived from the cleavage sequences of 3CLpro. After overe</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2026-06-15T06:04:59.965Z</modification><creation>2025-02-19T02:49:17.682Z</creation></dates><accession>S-EPMC9430692</accession><cross_references><pubmed>35758897</pubmed><doi>10.1128/spectrum.02559-21</doi></cross_references></HashMap>